Gregorio Encina

515 total citations
20 papers, 274 citations indexed

About

Gregorio Encina is a scholar working on Pharmacology, Small Animals and Molecular Biology. According to data from OpenAlex, Gregorio Encina has authored 20 papers receiving a total of 274 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 7 papers in Small Animals and 5 papers in Molecular Biology. Recurrent topics in Gregorio Encina's work include Inflammatory mediators and NSAID effects (10 papers), Veterinary Pharmacology and Anesthesia (7 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Gregorio Encina is often cited by papers focused on Inflammatory mediators and NSAID effects (10 papers), Veterinary Pharmacology and Anesthesia (7 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Gregorio Encina collaborates with scholars based in Spain, United Kingdom and United States. Gregorio Encina's co-authors include Anna Vaqué, Mariano Sust, Marisol Escriche, Carlos R. Plata‐Saláman, Éric Sicard, Sebastián Videla, Adelaida Morte, Kevin J. Smith, J. Graham Nairn and José Miguel Vela and has published in prestigious journals such as European Journal of Pharmaceutics and Biopharmaceutics, British Journal of Clinical Pharmacology and Clinical Therapeutics.

In The Last Decade

Gregorio Encina

18 papers receiving 261 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregorio Encina Spain 8 86 73 70 49 48 20 274
Kelly-Ann S. Schlegel 3 38 0.4× 145 2.0× 39 0.6× 25 0.5× 8 0.2× 3 306
T. Ito Japan 10 53 0.6× 18 0.2× 9 0.1× 23 0.5× 19 0.4× 24 342
W. Wirth Germany 11 76 0.9× 34 0.5× 25 0.4× 27 0.6× 8 0.2× 44 349
Mizue Makimura Japan 11 192 2.2× 35 0.5× 5 0.1× 22 0.4× 15 0.3× 28 388
Philip I Hair New Zealand 9 132 1.5× 56 0.8× 20 0.3× 7 0.1× 2 0.0× 12 385
Anu Gore United States 6 80 0.9× 19 0.3× 4 0.1× 159 3.2× 133 2.8× 8 511
Deying Gong China 11 119 1.4× 54 0.7× 8 0.1× 58 1.2× 1 0.0× 36 400
W. Hespe United States 10 158 1.8× 66 0.9× 18 0.3× 9 0.2× 3 0.1× 30 438
Elena Atanasova United States 8 224 2.6× 58 0.8× 4 0.1× 23 0.5× 5 0.1× 21 504
Sophie Dufaÿ France 10 37 0.4× 20 0.3× 9 0.1× 15 0.3× 3 0.1× 19 337

Countries citing papers authored by Gregorio Encina

Since Specialization
Citations

This map shows the geographic impact of Gregorio Encina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregorio Encina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregorio Encina more than expected).

Fields of papers citing papers by Gregorio Encina

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregorio Encina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregorio Encina. The network helps show where Gregorio Encina may publish in the future.

Co-authorship network of co-authors of Gregorio Encina

This figure shows the co-authorship network connecting the top 25 collaborators of Gregorio Encina. A scholar is included among the top collaborators of Gregorio Encina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregorio Encina. Gregorio Encina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fernández‐Pastor, Begoña, Mónica Garcı́a, Javier Burgueño, et al.. (2022). Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids. Acta Pharmaceutica Sinica B. 13(1). 82–99. 4 indexed citations
2.
Carlson, James D., Gregorio Encina, Mariano Sust, et al.. (2021). Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. Clinical Therapeutics. 43(6). 1051–1065. 27 indexed citations
3.
4.
Encina, Gregorio, et al.. (2021). Twenty six-week repeat dose oral rat toxicity study of cizolirtine, a substance-P and calcitonin gene-related peptide release modulator. Regulatory Toxicology and Pharmacology. 122. 104916–104916.
5.
Homedes, Josep, et al.. (2021). Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration. Journal of Veterinary Pharmacology and Therapeutics. 44(6). 888–901. 7 indexed citations
6.
Homedes, Josep, et al.. (2021). Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans:Main Metabolites and Proposed Metabolic Pathways. Drug Metabolism Letters. 14(3). 206–218. 1 indexed citations
7.
Almansa, Carmen, Manuel Merlos, José Miguel Vela, et al.. (2019). Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic. Expert Opinion on Investigational Drugs. 28(5). 399–409. 34 indexed citations
8.
Mundin, Gill, et al.. (2018). Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label Study. European Journal of Drug Metabolism and Pharmacokinetics. 44(1). 63–75. 7 indexed citations
9.
10.
Videla, Sebastián, Anna Vaqué, Mariano Sust, et al.. (2017). Single‐dose pharmacokinetics of co‐crystal of tramadol–celecoxib: Results of a four‐way randomized open‐label phase I clinical trial in healthy subjects. British Journal of Clinical Pharmacology. 83(12). 2718–2728. 41 indexed citations
11.
Videla, Sebastián, Anna Vaqué, Mariano Sust, et al.. (2017). Pharmacokinetics of multiple doses of co‐crystal of tramadol–celecoxib: findings from a four‐way randomized open‐label phase I clinical trial. British Journal of Clinical Pharmacology. 84(1). 64–78. 23 indexed citations
12.
13.
Videla, Sebastián, et al.. (2012). Food Effects on the Pharmacokinetics of Doxylamine Hydrogen Succinate 25 mg Film-Coated Tablets. Drugs in R&D. 12(4). 217–225. 7 indexed citations
14.
Videla, Sebastián, et al.. (2012). Food Effects on the Pharmacokinetics of Doxylamine Hydrogen Succinate 25 mg Film-Coated Tablets. Drugs in R&D. 12(4). 217–225. 1 indexed citations
15.
Escriche, Marisol, et al.. (2012). Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma‐1 receptor antagonist in three randomized phase I studies. British Journal of Clinical Pharmacology. 75(1). 103–117. 61 indexed citations
16.
Escriche, Marisol, Mariano Sust, Stéphanie Puig, et al.. (2010). 446 PHARMACOKINETIC PROFILE OF A SELECTIVE SIGMA‐1 RECEPTOR ANTAGONIST (S1RA) IN HUMAN. European Journal of Pain Supplements. 4(S1). 126–126. 1 indexed citations
17.
Encina, Gregorio, et al.. (2006). Comparative bioavailability between two tramadol once-daily oralformulations. Methods and Findings in Experimental and Clinical Pharmacology. 28(6). 373–373. 11 indexed citations
18.
19.
Encina, Gregorio, et al.. (1995). BIOPHARMACEUTICAL EVALUATION OF MICROCAPSULATED ION EXCHANGE RESINS CONTAINING DICLOFENAC. European Journal of Pharmaceutics and Biopharmaceutics. 41(2). 127–134. 12 indexed citations
20.
Encina, Gregorio, et al.. (1992). Phase diagram studies of microcapsule formation using hydroxypropyl methylcellulose phthalate. Drug Development and Industrial Pharmacy. 18(5). 561–579. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kelly-Ann S. Schlegel Breakdown of academic impact, for papers by T. Ito Breakdown of academic impact, for papers by W. Wirth Breakdown of academic impact, for papers by Mizue Makimura Breakdown of academic impact, for papers by Philip I Hair Breakdown of academic impact, for papers by Anu Gore Breakdown of academic impact, for papers by Deying Gong Breakdown of academic impact, for papers by W. Hespe Breakdown of academic impact, for papers by Elena Atanasova Breakdown of academic impact, for papers by Sophie Dufaÿ
Rankless by CCL
2026